TME Pharma appoints Diede van den Ouden as new CEO at the 2025 Annual General Meeting

TME Pharma N.V., a clinical-stage biotech company focused on developing novel cancer therapies, has announced the unanimous appointment of Diede van den Ouden as its new Chief Executive Officer and sole member of the Board of Directors at the 2025 Annual General Meeting (AGM). He succeeds Dr. Aram Mangasarian, who successfully led the company for many years and will remain involved in an advisory capacity.

Chairman of the Supervisory Board, Maurizio PetitBon, stated: “Diede’s commitment as an active supporter and significant shareholder gives us great confidence in this leadership transition.” He also expressed gratitude to Mangasarian for his instrumental contributions, particularly in advancing clinical data for the treatment of glioblastoma, one of the most challenging cancer types.

Diede van den Ouden said: “TME Pharma is at a critical inflection point – marked by clinical momentum and financial stability. I’m honored to lead this transformation and to drive our core programs, NOX-A12 and NOX-E36, forward.”

TME Pharma specializes in therapies that target the tumor microenvironment (TME) to enhance the immune system’s ability to fight cancer. With its lead candidates NOX-A12 and NOX-E36, the company has a promising pipeline targeting glioblastoma, pancreatic cancer, and colorectal cancer. Regulatory achievements such as Fast Track and Orphan Drug Designations highlight the company’s innovation potential.

This leadership transition marks a clear signal of TME Pharma’s strategic refocus and growth ambitions in the global oncology market.